Main molecular contacts <5 Å among the components of the prothrombin-fVa-fXa complex
fVa-fXa . | Prothrombin-fXa . | Prothrombin-fVa . |
---|---|---|
A511-L352(c170) | K307-Q240(c61) | L260-T305* |
A511-I357(c175) | D318-R405(c222) | D261-K309* |
F576-R347(c165) | D318-K408(c224) | D265-K309* |
D577-R347(c165) | R320-E372(c188) | R266-A694* |
T579-K351(c169) | E323-K330(c148) | E269-R505 |
T626-N348(c166) | D326-K242(c62) | R271-D697* |
D628-R347(c165) | R310-Y698 | |
E662-R306(c125)* | L312-Y698 | |
E662-K420(c236)* | L313-L702* | |
E669-R306(c125) | P534-Y696* | |
E672-R306(c125)* | F535-Y696* | |
E672-Q360(c178)* | ||
E672-K414(c230)* | ||
V675-R424(c240)* | ||
E686-K276(c96) | ||
S1598-E82 | ||
T1679-F84 | ||
H1683-L91 | ||
Y2021-E39* |
fVa-fXa . | Prothrombin-fXa . | Prothrombin-fVa . |
---|---|---|
A511-L352(c170) | K307-Q240(c61) | L260-T305* |
A511-I357(c175) | D318-R405(c222) | D261-K309* |
F576-R347(c165) | D318-K408(c224) | D265-K309* |
D577-R347(c165) | R320-E372(c188) | R266-A694* |
T579-K351(c169) | E323-K330(c148) | E269-R505 |
T626-N348(c166) | D326-K242(c62) | R271-D697* |
D628-R347(c165) | R310-Y698 | |
E662-R306(c125)* | L312-Y698 | |
E662-K420(c236)* | L313-L702* | |
E669-R306(c125) | P534-Y696* | |
E672-R306(c125)* | F535-Y696* | |
E672-Q360(c178)* | ||
E672-K414(c230)* | ||
V675-R424(c240)* | ||
E686-K276(c96) | ||
S1598-E82 | ||
T1679-F84 | ||
H1683-L91 | ||
Y2021-E39* |
Residues are numbered sequentially and for fXa also according to chymotrypsin by parentheses.
Residues of fVa not previously listed as potential epitopes of recognition of prothrombin or fXa by a recent review of biochemical data and computational models.66 The review lists a total of 56 residues of the A2 domain and 35 residues of the A3 domain of fVa involved in the interaction with fXa. The cryo-EM structure documents only 11 residues in the A2 domain (A511, F576, D577, T579, T626, D628, E662, E669, E672, V675, E686), 3 of which not reported previously (E662, E672, V675), 3 in the A3 domain (S1598, T1679, H1683) and 1 in the C1 domain (Y2021) also not reported previously. The main interactions are shown in Figure 4B-C. The review also lists 23 residues in the A2 domain, 18 in the A3 domain and 10 in the C1 domain as interacting with prothrombin.66 The cryo-EM structure documents 2 residues in the A1 domain (T305, K309) not reported previously, 6 residues in the A2 domain (R505, A694, Y696, D697, Y698, L702), 4 of which (A694, Y696, D697, L702) not reported previously, and no contacts involving the A3 and C1 domains.